SALT LAKE CITY
Aug. 2, 2012
/PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced the closing of the acquisition of World Heart Corporation following the approval of the transaction today by World Heart stockholders.
Under the terms of the merger agreement, HeartWare acquired all of the outstanding voting securities of World Heart for merger consideration of approximately
in HeartWare common stock, as calculated in accordance with the terms of the merger agreement. Each share of World Heart common stock has been converted into the right to receive 0.003 shares of HeartWare common stock.
"We are pleased with the pace of this transaction and anticipate moving quickly to integrate World Heart," said
, President and Chief Executive Officer of HeartWare. "Consistent with our goal to be a leader in the VAD market for years to come, we believe that bolstering our patent portfolio and adding World Heart's technologies broadens our options for the future."
The boards of directors of both companies previously approved the transaction, which was approved by World Heart's stockholders at a special stockholders meeting today. HeartWare stockholder approval was not required. Following the transaction and the issuance of approximately 83,000 new shares of HeartWare common stock to World Heart stockholders, HeartWare will have approximately 14,275,000 shares of common stock outstanding.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare
Ventricular Assist System features the HVAD
pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia. The device is currently the subject of
clinical trials for two indications: bridge-to-transplant and destination therapy. For additional information, please visit